Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before the bell. Here’s what investors should know.
Pfizer beat analysts’ revenue expectations last quarter, reporting revenues of $17.56 billion, down 1.2% year on year. It was a mixed quarter for the company, with an impressive beat of analysts’ revenue estimates but a significant miss of analysts’ organic revenue estimates.
Is Pfizer a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting Pfizer’s revenue to be flat year on year, improving from the 7.8% decrease it recorded in the same quarter last year.
Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing in majority downward revisions over the last 30 days. Pfizer rarely misses Wall Street’s revenue estimates.
Looking at Pfizer’s peers in the branded pharmaceuticals segment, some have already reported their Q1 results, giving us a hint as to what we can expect. Eli Lilly delivered year-on-year revenue growth of 55.5%, beating analysts’ expectations by 13.7%, and Merck reported revenues up 4.9%, topping estimates by 3%. Eli Lilly traded up 13.2% following the results while Merck was also up 1%.
Read our full analysis of Eli Lilly’s results here and Merck’s results here.
There has been positive sentiment among investors in the branded pharmaceuticals segment, with share prices up 6% on average over the last month. Pfizer is down 5.2% during the same time and is heading into earnings with an average analyst price target of $29.00 (compared to the current share price of $26.38).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a $437 billion giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
